The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional

JANUMET: Proven across a range of clinical studiesa

aAs an adjunct to diet and exercise.

Start with the power of JANUMET

For patients with high A1C levels

  • Powerful A1C reductions vs metformin alone.
  • Superior goal-getting power vs metformin alone.
  • Rates of gastrointestinal adverse events, hypoglycemic episodes, and weight loss similar to metformin alone.
  • More than 90% of patients in commercial plans are covered at the lowest branded co-pay without prior authorizations.b,c

bFingertip Formulary, LLC. July 2011.
c Among oral antidiabetics and Glucagon-like peptide-1s.

Important Information
JANUMET is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

JANUMET should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUMET.

Please read the Boxed Warning about lactic acidosis.

 

Janice

  • 42 years old, 5’4”, 181 lb
  • BMI: 31.1
  • Recently diagnosed with type 2 diabetes
  • Prefers oral medications
  • Concerned about cholesterol and weight
  • Current A1C: 8.8%

For appropriate patients with type 2 diabetes, start with the power of JANUMET


John

  • 65 years old, 5’8”, 195 lb
  • BMI: 29.6
  • Type 2 diabetes is uncontrolled on diet and exercise
  • Recent angioplasty
  • Treated for hypertension and hypercholesterolemia
  • Current A1C: 9.0%

For appropriate patients with type 2 diabetes, start with JANUMET to get nearly twice as many patients to goal 9

Close
9.
Goldstein BJ, Feinglos MN, Lunceford JK, et al; for Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987. Dr. Goldstein is currently an employee at Merck, but was in academia at the time of publication.
Close
56.
Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DIAB-1019966-0000 12/11.
Close
57.
Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652.
Close
57.
Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652.